CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorZhejiang University
About this trial
This is a single-arm, open-label, single-center, phase I/II study. The primary objective is to evaluate the safety of CD7 CAR-T Bridging to allo-HSCT therapy for patients with CD7-positive relapsed or refractory Malignant Hematologic Diseases
Eligibility criteria
Qualifiers
Provision of signed and dated informed consent form (ICF)
Male or female, older than 18 years (including 18 years)
Anticipated survival time more than 12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
Disqualifiers
Patients with the history of epilepsy or other CNS disease
Pregnant or breastfeeding
Active infection with no cure
Patients with prolonged QT interval time or severe heart disease
Trial design
Treatments tested in this trial
- CD7 CAR-T cells injection
- Allogeneic hematopoietic stem cell transplantation
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Zhejiang University
Lead sponsor
Yake Biotechnology Ltd.
Collaborator
Source ClinicalTrials.gov